Form 4: Oramed CEO Kidron Boosts Stake with Equity Awards

Oramed Pharmaceuticals CEO Nadav Kidron acquired significant equity awards, including Restricted Stock Units and Performance Stock Units, aligning his interests with long-term company performance.

Summary

• Nadav Kidron, President and CEO of Oramed Pharmaceuticals Inc. (ORMP), reported the acquisition of various equity securities.
• On December 31, 2025, Kidron acquired 232,640 Restricted Stock Units (RSUs) which vested in full on January 1, 2026.
• Also on December 31, 2025, an additional 327,000 RSUs were acquired, set to vest in quarterly installments over a three-year period starting January 1, 2026.
• Each RSU represents the right to receive one share of Oramed's common stock, par value $0.012 per share.
• Kidron also acquired 109,000 Performance Stock Units (PSUs) on December 31, 2025, which represent a contingent right to receive one share of common stock.
• These PSUs vest upon the achievement of either a specified common stock price per share or applicable performance criteria.
• Following these transactions, Kidron directly beneficially owns 3,246,238 shares of common stock and 109,000 PSUs.
• Additionally, 126,000 shares of common stock are indirectly beneficially owned by a wholly-owned corporation.

Sentiment

Score: 7

Explanation: The filing indicates increased insider ownership and alignment of management incentives with shareholder interests through equity awards, which is generally a positive signal for investors, though it is a routine compensation disclosure.

Positives

• Increased beneficial ownership by the President and CEO, Nadav Kidron, signals strong alignment of management interests with long-term shareholder value.
• The acquisition of performance-based units (PSUs) ties a portion of the CEO's compensation directly to the achievement of specific company performance criteria or stock price targets.

Risks

• The vesting of Performance Stock Units (PSUs) is contingent on achieving specified stock prices or performance criteria, introducing uncertainty regarding their ultimate realization.
• The value of the acquired RSUs and PSUs is subject to the future market price of Oramed's common stock.

Future Outlook

The future outlook includes the vesting of 232,640 RSUs on January 1, 2026, and the quarterly vesting of 327,000 RSUs over a three-year period starting January 1, 2026. Additionally, 109,000 PSUs are contingent on achieving specified stock price targets or performance criteria.

Industry Context

The acquisition of equity awards by a CEO is a standard practice in the pharmaceutical and biotechnology industries, serving as a key component of executive compensation to align leadership incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Pfizer, Moderna, or Johnson & Johnson, which frequently utilize such equity-based incentives.
• The vesting schedules, particularly the three-year quarterly vesting for a portion of the RSUs and performance-based vesting for PSUs, are consistent with typical industry standards designed to promote long-term retention and performance.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of the CEO's financial interests with the company's long-term performance and stock value.
• Employees: No direct impact mentioned, but a strong leadership team with aligned incentives can positively influence overall company direction and stability.

Next Steps

• The 232,640 RSUs will vest in full on January 1, 2026.
• The 327,000 RSUs will begin vesting in quarterly installments over a three-year period starting January 1, 2026.
• The 109,000 PSUs will vest upon the achievement of specified stock price targets or applicable performance criteria.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for the CEO, increasing his beneficial ownership. While it signals management's continued alignment with shareholder interests, it does not provide new fundamental information to warrant a change in investment recommendation based solely on this report. The company's overall financial health, pipeline progress, and market conditions remain the primary drivers for investment decisions.

Keywords

Oramed Pharmaceuticals, ORMP, Nadav Kidron, Form 4, Insider Transaction, Equity Awards, Restricted Stock Units, RSU, Performance Stock Units, PSU, Stock Ownership, CEO Compensation